Literature DB >> 10208955

An inborn error of bile acid synthesis (3beta-hydroxy-delta5-C27-steroid dehydrogenase deficiency) presenting as malabsorption leading to rickets.

A K Akobeng1, P T Clayton, V Miller, M Super, A G Thomas.   

Abstract

Deficiency of 3beta-hydroxy-delta5-C27-steroid dehydrogenase (3beta-HSDH), the enzyme that catalyses the second reaction in the principal pathway for the synthesis of bile acids, has been reported to present with prolonged neonatal jaundice with the biopsy features of neonatal hepatitis. It has also been shown to present between the ages of 4 and 46 months with jaundice, hepatosplenomegaly, and steatorrhoea (a clinical picture resembling progressive familial intrahepatic cholestasis). This paper reports two children with 3beta-HSDH deficiency who developed rickets during infancy and did not develop clinically evident liver disease until the age of 3 years. Bile acid replacement resulted in considerable clinical and biochemical improvement. The importance of thorough investigation of fat soluble vitamin deficiencies in infancy is emphasised.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208955      PMCID: PMC1717927          DOI: 10.1136/adc.80.5.463

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

1.  3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology.

Authors:  S P Horslen; A M Lawson; M Malone; P T Clayton
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Trihydroxycoprostanic acid in the duodenal fluid of two children with intrahepatic bile duct anomalies.

Authors:  H Eyssen; G Parmentier; F Compernolle; J Boon; E Eggermont
Journal:  Biochim Biophys Acta       Date:  1972-06-26

3.  3-Oxo-delta 4 bile acids in liver disease.

Authors:  P T Clayton; E Patel; A M Lawson; R A Carruthers; M S Tanner; B Strandvik; B Egestad; J Sjövall
Journal:  Lancet       Date:  1988-06-04       Impact factor: 79.321

4.  Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis.

Authors:  K D Setchell; F J Suchy; M B Welsh; L Zimmer-Nechemias; J Heubi; W F Balistreri
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Treatment of chronic liver disease caused by 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid.

Authors:  H Ichimiya; H Nazer; T Gunasekaran; P Clayton; J Sjövall
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

6.  The metabolism of 3alpha, 7alpha, 12alpha-trihydorxy-5beta-cholestan-26-oic acid in two siblings with cholestasis due to intrahepatic bile duct anomalies. An apparent inborn error of cholic acid synthesis.

Authors:  R F Hanson; J N Isenberg; G C Williams; D Hachey; P Szczepanik; P D Klein; H L Sharp
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

7.  Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis?

Authors:  P T Clayton; M Casteels; G Mieli-Vergani; A M Lawson
Journal:  Pediatr Res       Date:  1995-04       Impact factor: 3.756

8.  Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids.

Authors:  P T Clayton; J V Leonard; A M Lawson; K D Setchell; S Andersson; B Egestad; J Sjövall
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

9.  A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency.

Authors:  E Jacquemin; K D Setchell; N C O'Connell; A Estrada; G Maggiore; J Schmitz; M Hadchouel; O Bernard
Journal:  J Pediatr       Date:  1994-09       Impact factor: 4.406

Review 10.  Inborn errors of bile acid metabolism.

Authors:  P T Clayton
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

  10 in total
  7 in total

1.  The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis.

Authors:  M Schwarz; A C Wright; D L Davis; H Nazer; I Björkhem; D W Russell
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology.

Authors:  Vered Molho-Pessach; Jonathan J Rios; Chao Xing; Kenneth D R Setchell; Jonathan C Cohen; Helen H Hobbs
Journal:  Hepatology       Date:  2012-02-08       Impact factor: 17.425

Review 3.  Diagnosis of inherited disorders of liver metabolism.

Authors:  P T Clayton
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 4.  Intestinal bile acid physiology and pathophysiology.

Authors:  Olga Martinez-Augustin; Fermin Sanchez de Medina
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

5.  Prognosis and clinical characteristics of patients with 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency diagnosed in childhood: A systematic review of the literature.

Authors:  Yuan Zhang; Chun-Feng Yang; Wen-Zhen Wang; Yong-Kang Cheng; Chu-Qiao Sheng; Yu-Mei Li
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

6.  Atypical clinical presentation and successful treatment with oral cholic acid of a child with defective bile acid synthesis due to a novel mutation in the HSD3B7 gene.

Authors:  Grazia Bossi; Giuseppe Giordano; Gaetana Anna Rispoli; Giuseppe Maggiore; Mauro Naturale; Daniela Marchetti; Maria Iascone
Journal:  Pediatr Rep       Date:  2017-10-10

7.  Genetic spectrum and clinical characteristics of 3β-hydroxy-Δ5-C27-steroid oxidoreductase (HSD3B7) deficiency in China.

Authors:  Jing Zhao; Kenneth D R Setchell; Ying Gong; Yinghua Sun; Ping Zhang; James E Heubi; Lingjuan Fang; Yi Lu; Xinbao Xie; Jingyu Gong; Jian-She Wang
Journal:  Orphanet J Rare Dis       Date:  2021-10-09       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.